Provided is an isolated CTLA4 monoclonal antibody. The antibody can highly-specifically bind to CTLA4, and can effectively block the binding of CTLA4 to B7, reduce the activity or expression level of CTLA4, relieve the inhibition of CTLA4 on the immune function of an organism, activate T lymphocytes, and effectively treat tumors and immune system diseases. Also provided are a monoclonal antibody conjugate comprising the pharmaceutical composition and diagnostic composition of the antibody, and the use thereof in the preparation of a drug for preventing and/or treating and/or treating in combination tumors and immune system diseases.

The present invention relates to a tumor-targeting protein or a fragment thereof, an antibody binding thereto and a use thereof. More specifically, the present invention relates to a vector containing a nucleic acid coding for the protein A56 or a fragment thereof, and a use thereof. In addition, the present invention relates to an antibody binding to the protein A56 or a fragment thereof, and a use thereof. The vector containing the nucleic acid coding for the protein A56, a fragment thereof or a mutant thereof of the present invention uses an oncolytic virus as the vector, and thus, when administered in an individual, specifically kills only cancer cells, primarily. In addition, cancer cells which have survived even after being infected with the oncolytic virus express the protein A56 on the cell surfaces thereof, and thus may be targeted for secondary anticancer therapy. Thus, cancer may be effectively treated when the vector containing the nucleic acid coding for the protein A56 or a fragment thereof, and the antibody binding to A56, according to one embodiment of the present invention, are used.

Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).

This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

Disclosed herein are tetrazines substituted with groups that result in a high click conjugation yield and high click release yields. In some of several other aspects, the invention relates to combinations and kits having the tetrazines and a dienophile, preferably a trans-cyclooctene. In another aspect, the compounds, combinations, and kits are for use as a medicament.

This invention relates to methods and compositions comprising antibodies or fragments thereof comprising a targeting ligand and engineered cytotoxic cells comprising a targeting agent specific for the targeting ligand, for use in inducing cytotoxicity in a cancer cell, in delivering a cytotoxic cell to a cancer cell in a subject, and in treating cancer.

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

Degrader-antibody conjugates (DACs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Degrader molecules as described comprise a ubiquitin E3 ligase binding group (E3LB) and a protein binding group (PB). Linkers may be utilized between the antibodies and the degrader molecules (L1) and between the ubiquitin E3 ligase binding group (E3LB) and the protein binding group (PB) of the degrader molecule (L2). Methods of use of said DACs are also described.

The present invention relates to conjugates and pharmaceutically acceptable salts thereof, reagents, intermediates, methods for the synthesis of said conjugates, pharmaceutical compositions comprising said conjugates and the use of said conjugates.